Streetbeat News

Price Targets

CERE

JP Morgan analyst Jessica Fye has reinstated coverage on Cerevel Therapeutics Holdings (CERE) with a Neutral rating and set a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:44 pm

DKNG

Needham analyst Bernie McTernan has reiterated a Buy rating on DraftKings (NASDAQ:DKNG) and maintained a $50 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:28 pm

GDYN

Needham analyst Mayank Tandon has reiterated a Buy rating on Grid Dynamics Holdings (NASDAQ:GDYN) and maintained a $14 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:26 pm

EG

Raymond James analyst C. Gregory Peters has reaffirmed a Strong Buy rating on Everest Group (NYSE:EG) and increased the price target from $455 to $460.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:25 pm

SKWD

Raymond James analyst C. Gregory Peters has reaffirmed a Strong Buy rating on Skyward Specialty (NASDAQ:SKWD) and increased the price target from $30 to $36.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:23 pm

MNR

Raymond James analyst John Freeman has initiated coverage on Mach Natural Resources (NYSE:MNR) with a Strong Buy rating and set a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:17 pm

GGB

B of A Securities analyst Caio Ribeiro downgraded Gerdau (NYSE:GGB) from Buy to Neutral and reduced the price target from $5.6 to $5.1.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:15 pm

HIVE

HC Wainwright & Co. analyst Mike Colonnese downgraded HIVE Digital Technologies (NASDAQ:HIVE) from Buy to Neutral and reduced the price target from $7 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:11 pm

SSRM

B of A Securities analyst Michael Jalonen has downgraded SSR Mining (NASDAQ:SSRM) from Buy to Underperform and reduced the price target from $17 to $12.5.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:08 pm

CVKD

HC Wainwright & Co. analyst Joseph Pantginis has initiated coverage on Cadrenal Therapeutics with a Buy rating and set a price target of $3. The company is listed on NASDAQ under the ticker CVKD.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:05 pm